Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Pharmacognosy CommunicationsNOW IN
    Article

    A Compound Isolated From a Chinese Herbal Medicine Inhibits Hepatitis C Virus Activity

    Ian Edwin Cock1,2★★ Corresponding author

    1. 1Environmental Futures Centre, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.
    2. 2School of NaturalSciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.

    CORRESPONDENCE

    Ian Edwin Cock

    Environmental Futures Centre, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.

    I.Cock@griffith.edu.au

    Volume 5, Issue 2 · pp. 161–162 · PUBLISHED · DOI:

    View on Pharmacogn. Commn. original site ↗

    ABSTRACT

    A recent study has identified a novel compound designated SBEL1 which is present in Chinese medicinal herb sourced from southern China and Taiwan as being effective in inhibiting the hepatitis C virus (HCV) lifecycle.1 Indeed, the compound can block HCV activity by as much as 90%. Whilst the ethnobotanical uses of the herb are not thought to include the treatment of hepatitis, it has traditionally been used in the treatment of several other diseases which may be due to viruses. Thus, the compound may also be useful in the treatment of other viral diseases. As yet, the antiviral mechanism of SBEL1 is unknown although early testing indicates that the compound may have a pleuripotent mechanism. Pre-treatment of liver cells with SBEL1 was found to block HCV viral entry. Furthermore, HCV RNA levels were reduced by approximately 80%, indicating that the compound may also block viral replication.

    KEYWORDS

      Open in new tab

      REFERENCES

      As published

      Showing references and in-text citations exactly as published.

        Cite this article

        SELECT FORMAT

        Cock, I. E. (). A Compound Isolated From a Chinese Herbal Medicine Inhibits Hepatitis C Virus Activity. Pharmacognosy Communications, 5(2), 161–162.